Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 4
1974 2
1975 2
1976 2
1977 2
1978 3
1979 1
1980 4
1981 6
1982 6
1983 3
1984 7
1985 5
1986 7
1987 5
1988 10
1989 11
1990 9
1991 5
1992 12
1993 15
1994 10
1995 12
1996 12
1997 13
1998 17
1999 15
2000 7
2001 6
2002 16
2003 16
2004 24
2005 17
2006 24
2007 19
2008 24
2009 22
2010 27
2011 35
2012 51
2013 41
2014 49
2015 59
2016 53
2017 66
2018 69
2019 76
2020 73
2021 94
2022 72
2023 71
2024 36

Text availability

Article attribute

Article type

Publication date

Search Results

1,114 results

Results by year

Filters applied: . Clear all
Page 1
Novel Biomarkers in Membranous Nephropathy.
Liu Q, Liu J, Lin B, Zhang Y, Ma M, Yang M, Qin X. Liu Q, et al. Front Immunol. 2022 Apr 22;13:845767. doi: 10.3389/fimmu.2022.845767. eCollection 2022. Front Immunol. 2022. PMID: 35529848 Free PMC article. Review.
Timely diagnosis and reasonable intervention are the keys to improving prognosis. In recent years, with the development of high-throughput technologies, such as mass spectrometry (MS), microarray, and sequencing technologies, the discovery of biomarkers for MN has become a …
Timely diagnosis and reasonable intervention are the keys to improving prognosis. In recent years, with the development of high-throu …
Membranous nephropathy.
Dantas M, Silva LBB, Pontes BTM, Dos Reis MA, de Lima PSN, Moysés Neto M. Dantas M, et al. J Bras Nefrol. 2023 Apr-Jun;45(2):229-243. doi: 10.1590/2175-8239-JBN-2023-0046en. J Bras Nefrol. 2023. PMID: 37527529 Free PMC article. Review.
Great advances in the identification of potential target antigens have occurred in the last twenty years, and the main one is the protein "M-type phospholipase-A2 receptor" (PLA2R) with the circulating anti-PLA2R antibody, which makes it possible to evaluate the activity and p …
Great advances in the identification of potential target antigens have occurred in the last twenty years, and the main one is the protein "M …
Primary membranous nephropathy: comprehensive review and historical perspective.
Keri KC, Blumenthal S, Kulkarni V, Beck L, Chongkrairatanakul T. Keri KC, et al. Postgrad Med J. 2019 Jan;95(1119):23-31. doi: 10.1136/postgradmedj-2018-135729. Epub 2019 Jan 25. Postgrad Med J. 2019. PMID: 30683678 Review.
Anti-PLA2R antibody is the first serologic marker that has promising evidence to be used as a tool to prognosticate the course of the disease. More importantly, therapeutic agents such as rituximab and adrenocorticotropic hormone analogues are the newer therapeutic …
Anti-PLA2R antibody is the first serologic marker that has promising evidence to be used as a tool to prognosticate the course …
Exostosin 1/Exostosin 2-Associated Membranous Nephropathy.
Sethi S, Madden BJ, Debiec H, Charlesworth MC, Gross L, Ravindran A, Hummel AM, Specks U, Fervenza FC, Ronco P. Sethi S, et al. J Am Soc Nephrol. 2019 Jun;30(6):1123-1136. doi: 10.1681/ASN.2018080852. Epub 2019 May 6. J Am Soc Nephrol. 2019. PMID: 31061139 Free PMC article.
Advances in the Management of Primary Membranous Nephropathy and Rituximab-Refractory Membranous Nephropathy.
Teisseyre M, Cremoni M, Boyer-Suavet S, Ruetsch C, Graça D, Esnault VLM, Brglez V, Seitz-Polski B. Teisseyre M, et al. Front Immunol. 2022 May 4;13:859419. doi: 10.3389/fimmu.2022.859419. eCollection 2022. Front Immunol. 2022. PMID: 35603210 Free PMC article. Review.
Primary membranous nephropathy (pMN) is an auto-immune disease characterized by auto-antibodies targeting podocyte antigens resulting in activation of complement and damage to the glomerular basement membrane. pMN is the most common cause of nephrotic syndrome in adults without d …
Primary membranous nephropathy (pMN) is an auto-immune disease characterized by auto-antibodies targeting podocyte antigens resulting in act …
Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up.
Dahan K, Debiec H, Plaisier E, Cachanado M, Rousseau A, Wakselman L, Michel PA, Mihout F, Dussol B, Matignon M, Mousson C, Simon T, Ronco P; GEMRITUX Study Group. Dahan K, et al. J Am Soc Nephrol. 2017 Jan;28(1):348-358. doi: 10.1681/ASN.2016040449. Epub 2016 Jun 27. J Am Soc Nephrol. 2017. PMID: 27352623 Free PMC article. Clinical Trial.
Cytokines network in primary membranous nephropathy.
Zhao Q, Dai H, Hu Y, Jiang H, Feng Z, Liu W, Dong Z, Tang X, Hou F, Rui H, Liu B. Zhao Q, et al. Int Immunopharmacol. 2022 Dec;113(Pt A):109412. doi: 10.1016/j.intimp.2022.109412. Epub 2022 Nov 8. Int Immunopharmacol. 2022. PMID: 36461585 Review.
Autoantibodies, being the end product of humoral auto-immunity, matter much in diagnosis, therapy and prediction. Although PMN has been thought of as oligoinflammatory glomerulopathy, autoimmune diseases usually involve inflammation and it may be long-lasting. ...
Autoantibodies, being the end product of humoral auto-immunity, matter much in diagnosis, therapy and prediction. Although PMN has be …
Membranous nephropathy.
Ponticelli C. Ponticelli C. J Nephrol. 2007 May-Jun;20(3):268-87. J Nephrol. 2007. PMID: 17557260 Review.
Membranous nephropathy (MN) is a glomerular disease characterized by proteinuria, usually in a nephrotic range, and variable natural course. The etiology is unknown in many cases, while in some patients, MN may be secondary to infection, to other diseases, or to exposure t …
Membranous nephropathy (MN) is a glomerular disease characterized by proteinuria, usually in a nephrotic range, and variable natural cour …
1,114 results